Combigene AB (COMBI) - Total Assets
Based on the latest financial reports, Combigene AB (COMBI) holds total assets worth Skr75.88 Million SEK (≈ $8.17 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Combigene AB (COMBI) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Combigene AB - Total Assets Trend (2012–2024)
This chart illustrates how Combigene AB's total assets have evolved over time, based on quarterly financial data. Check how high is Combigene AB's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Combigene AB - Asset Composition Analysis
Current Asset Composition (December 2024)
Combigene AB's total assets of Skr75.88 Million consist of 99.0% current assets and 1.0% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 97.2% |
| Accounts Receivable | Skr0.00 | 0.0% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Combigene AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see COMBI market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Combigene AB's current assets represent 99.0% of total assets in 2024, an increase from 2.7% in 2012.
- Cash Position: Cash and equivalents constituted 97.2% of total assets in 2024, up from 0.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 97.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Combigene AB Competitors by Total Assets
Key competitors of Combigene AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Combigene AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.47 | 24.84 | 0.54 |
| Quick Ratio | 17.47 | 25.27 | 0.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr70.82 Million | Skr99.08 Million | Skr-11.69 Million |
Combigene AB - Advanced Valuation Insights
This section examines the relationship between Combigene AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.68 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -37.1% |
| Total Assets | Skr75.88 Million |
| Market Capitalization | $5.24 Million USD |
Valuation Analysis
Below Book Valuation: The market values Combigene AB's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Combigene AB's assets decreased by 37.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Combigene AB (2012–2024)
The table below shows the annual total assets of Combigene AB from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr75.88 Million ≈ $8.17 Million |
-37.09% |
| 2023-12-31 | Skr120.61 Million ≈ $12.98 Million |
-23.77% |
| 2022-12-31 | Skr158.22 Million ≈ $17.03 Million |
-4.81% |
| 2021-12-31 | Skr166.22 Million ≈ $17.89 Million |
+109.31% |
| 2020-12-31 | Skr79.41 Million ≈ $8.55 Million |
+81.23% |
| 2019-12-31 | Skr43.82 Million ≈ $4.72 Million |
+24.78% |
| 2018-12-31 | Skr35.12 Million ≈ $3.78 Million |
+331.45% |
| 2017-12-31 | Skr8.14 Million ≈ $875.90K |
+66.47% |
| 2016-12-31 | Skr4.89 Million ≈ $526.15K |
-55.38% |
| 2015-12-31 | Skr10.96 Million ≈ $1.18 Million |
+75.39% |
| 2014-12-31 | Skr6.25 Million ≈ $672.31K |
+876.79% |
| 2013-12-31 | Skr639.58K ≈ $68.83K |
+7.55% |
| 2012-12-31 | Skr594.67K ≈ $64.00K |
-- |
About Combigene AB
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures. The… Read more